Our mission
We strive to develop innovative therapeutics, to eliminate cancers, and prevent recurrence.
We aim to provide better and more accessible treatment options to diverse patient populations around the world.
We fight every day because we know patients do too.
Confront Challenging Conditions
Maximize Benefit of Local and Regional Delivery
Patients First
Streamlined Solution-Focused Research and Development
Pipeline
The lead indication of the PRV System is oral cancer, followed by oral carcinoma in situ and intra-operative chemotherapy cancers. Privo’s Phase II clinical study on oral cancer has successfully completed meeting all of its primary and secondary endpoints. Privo oral carcinoma in situ is in phase 3
Recognition
Privo is excited to work closely with its collaborators at the FDA, the NCI and the NIDCR.
Privo Technologies has received over $20M in nondilutive funding from these institutions in support of its product development and clinical trial.
News
Privo Technologies Receives $4.5M Funding from National Cancer Institute for Phase 3 Clinical Trial of Innovative Oral Cancer Treatment
Privo Technologies is proud to announce the receipt of $4.5...
Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors
Privo Technologies, Inc. is pleased to announce that it...
Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the...
- © UX Strategy & Digital Branding
